These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30878303)

  • 1. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS).
    Bratt O; Holmberg E; Andrén O; Carlsson S; Drevin L; Johansson E; Josefsson A; Nyberg M; Sandberg J; Stattin P; Robinsson D
    Eur Urol; 2019 Oct; 76(4):461-466. PubMed ID: 30878303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
    Voss J; Pal R; Ahmed S; Hannah M; Jaulim A; Walton T
    BJU Int; 2018 Jun; 121(6):863-870. PubMed ID: 29239082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised trial comparing two protocols for transrectal prostate repeat biopsy: six lateral posterior plus six anterior cores versus a standard posterior 12-core biopsy.
    Örtegren J; Holmberg JT; Lekås E; Mana S; Mårtensson S; Richthoff J; Sundqvist P; Kjölhede H; Bratt O; Liedberg F
    Scand J Urol; 2019 Aug; 53(4):217-221. PubMed ID: 31204873
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
    Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
    Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.
    Umbehr MH; Platz EA; Peskoe SB; Bhavsar NA; Epstein JI; Landis P; Partin AW; Carter HB
    BJU Int; 2014 Apr; 113(4):561-7. PubMed ID: 23746233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
    Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
    Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
    Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
    Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
    Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
    Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.
    Ouzzane A; Renard-Penna R; Marliere F; Mozer P; Olivier J; Barkatz J; Puech P; Villers A
    J Urol; 2015 Aug; 194(2):350-6. PubMed ID: 25747105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sampling of the anterior apical region results in increased cancer detection and upgrading in transrectal repeat saturation biopsy of the prostate.
    Seles M; Gutschi T; Mayrhofer K; Fischereder K; Ehrlich G; Gallé G; Gutschi S; Pachernegg O; Pummer K; Augustin H
    BJU Int; 2016 Apr; 117(4):592-7. PubMed ID: 25726856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
    Singh S; Sandhu P; Beckmann K; Santaolalla A; Dewan K; Clovis S; Rusere J; Zisengwe G; Challacombe B; Brown C; Cathcart P; Popert R; Dasgupta P; Van Hemelrijck M; Elhage O
    BJU Int; 2021 Jul; 128(1):72-78. PubMed ID: 33098158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transperineal Template-guided Mapping Biopsy Identifies Pathologic Differences Between Very-Low-risk and Low-risk Prostate Cancer: Implications for Active Surveillance.
    Merrick GS; Delatore A; Butler WM; Bennett A; Fiano R; Anderson R; Adamovich E
    Am J Clin Oncol; 2017 Feb; 40(1):53-59. PubMed ID: 25068472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Prostate HistoScanning as a Method for Targeted Biopsy in Routine Practice.
    Glybochko PV; Alyaev YG; Amosov AV; Krupinov GE; Nir D; Winkler M; Ganzha TM
    Eur Urol Focus; 2019 Mar; 5(2):179-185. PubMed ID: 28753891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
    Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
    Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
    Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
    Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance.
    Shapiro DD; Gregg JR; Lim AH; Nogueras-González GM; Choi H; Kang HC; Inguillo IA; Chapin BF; Davis JW; Ward JF
    BJU Int; 2021 Mar; 127(3):340-348. PubMed ID: 32357283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
    Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
    Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer.
    Barzell WE; Melamed MR; Cathcart P; Moore CM; Ahmed HU; Emberton M
    J Urol; 2012 Sep; 188(3):762-7. PubMed ID: 22818143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.